- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07671625
Comprehensive Perioperative Program Based on Prehabilitation, Nutritional Intervention and Psychological Support for Patients With Locally Advanced Operable Oesophagogastric Cancer (OESOFIT)
A Comprehensive Preoperative and Postoperative Program Consisting Of Active Physical Therapy, A Comprehensive Nutritional Plan, And Psychological Support For Patients With Locally Advanced, Resectable Cancer Of The Esophagus, Gastroesophageal Junction, and Stomach
Study Overview
Status
Detailed Description
Standard care for locally advanced diseases includes perioperative chemotherapy or preoperative chemoradiotherapy, which can, in turn, lead to patient deconditioning prior to surgery. Efforts to overcome these complications led to the development of the ERAS (Enhanced Recovery After Surgery) program. This program overlaps with the emerging concept of prehabilitation/pre-optimization, which is based on identifying risk factors, formulating nutritional support, creating an exercise plan to improve overall physical fitness, and implementing continuous psychological support to enhance the patient's postoperative recovery.
The autonomic nervous system (ANS) is the body's primary homeostatic regulatory system, which can be negatively affected by anticancer treatment. Heart rate variability (HRV) is a suitable candidate for monitoring ANS function and can provide early indication of a deterioration in the sympathovagal balance of test subjects. As mentioned above, preoperative chemotherapy may further affect ANS function. It is known that regimens based on oxaliplatin and paclitaxel cause peripheral neuropathy and are associated with a significant impact on the adrenergic cardiovascular response and parasympathetic cardiac innervation. We hypothesize that a controlled increase in physical cardiorespiratory fitness during the preoperative period could improve HRV and aerobic performance, taking into account the patient's current condition. An integral part of a comprehensive program should also be perioperative individualized nutritional support aimed at maintaining body weight and muscle mass. The most common adverse effects of cancer treatment include cardiac toxicity, peripheral neuropathy, cachexia, loss of appetite, cognitive changes, fatigue, nausea, pain, and sleep disturbances, which have a significant impact on patients' quality of life. For this reason, special attention must also be paid to psychological support during active cancer treatment and in follow-up care. Psychological assessment should serve as a long-term tool for patients and families both during and after the active treatment course. Considering all the above aspects, a comprehensive assessment prior to treatment initiation and a specialized comprehensive program should be approached as a prehabilitation process. Furthermore, this concept, together with ERAS and six-month postoperative follow-up, constitutes optimal management of patients with esophageal cancer.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Martina Lojová, PhD
- Phone Number: +420543136232
- Email: martina.lojova@mou.cz
Study Contact Backup
- Name: Tereza Štěpánková, PhD
- Phone Number: +420543136223
- Email: tereza.stepankova@mou.cz
Study Locations
-
-
-
Brno, Czechia, 65653
- Recruiting
- Masaryk Memorial Cancer Institute
-
Contact:
- Martina Lojová, PhD
- Phone Number: +420543136232
- Email: martina.lojova@mou.cz
-
Contact:
- Tereza Štěpánková, PhD
- Phone Number: +420543136223
- Email: tereza.stepankova@mou.cz
-
Principal Investigator:
- Radka Lordick Obermannová, Doc, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Consent to participate in the study
- Age ≥ 18 years
- Patients with locally advanced esophageal or gastric cancer indicated for comprehensive perioperative treatment
- Resectable disease
- ECOG performance status 0-2
- Ability to participate in a fitness program
- Willingness to follow a nutritional plan and recommendations
Exclusion Criteria:
- Disseminated disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Interventional
Participants undergo a multimodal prehabilitation and perioperative optimization program.
Intervention includes supervised home-based exercise training prescribed according to the ACSM FITT principles for 8 weeks, incorporating inspiratory muscle training initiated at 60% of baseline maximal inspiratory pressure and progressively adjusted based on perceived exertion, together with aerobic exercise at 60-80% heart rate reserve.
Training is delivered via telemedicine with regular remote supervision.
Cardiorespiratory fitness is assessed at baseline, after completion of neoadjuvant therapy, and 6 months postoperatively.
Participants will receive comprehensive nutritional assessment and individualized nutritional support, structured psychological counseling at predefined study time points, and perioperative care according to ERAS principles.
Quality of life is evaluated using validated questionnaires.
Cellular and humoral immunity and endocrine function are monitored longitudinally using
|
A single measurement before the start of preoperative treatment (baseline), after completion of chemotherapy 4-2 weeks before surgery, and 6 months after surgery.
Exercise training is prescribed in accordance with the guidelines for prescribing physical activity (the FITT methodology published by the ACSM in 2018) for a period of 2 months.
Training is set at 60% of the baseline maximum inspiratory pressure (MIP) and is increased by 5% if the participant reports a rate of perceived exertion (RPE) < 7 (RPE scale 1-10).
Exercises is conducted under supervision using telemedicine technologies.
Weekly online check-ins via video call using the MOU MEDDI platform (first 4 weeks), then once every 14 days.
Alternatively, weekly training sessions at the gym for the first 4 weeks (3 times a week at home, walking for at least 30 minutes per training session), followed by independent training at home.
The intensity of aerobic training is prescribed based on a target heart rate of 60-80% of the heart rate reserve.
An important part of the evaluation is also the patient's adherence to the exercise intervention and their level of physical activity.
Psychological intervention is provided to each patient at the following time points: 1) upon enrollment in the study, 2) before surgery, 3) 30 days after surgery, and 4) 6 months after surgery.
It is assessed using standardized questionnaires.
Monitoring of cellular and humoral immunity/endocrine function will be performed by flow cytometry using two peripheral blood samples (1 tube containing 2.7 mL of EDTA-anticoagulated blood and 1 tube containing 5 mL of anticoagulant-free blood for serum separation) at 4 time points: 1) upon study enrollment, 2) before surgery, 3) 30 days after surgery, and 4) 6 months after surgery.
Multicolor (6 to 8 colors) protocols for the proposed immune profile have already been established.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Autonomic Nervous System Balance as Measured by Heart Rate Variability
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Evaluation of the root mean square of successive differences in milliseconds between heartbeats to assess parasympathetic activity.
|
Baseline (pre-intervention), Perioperative, 1 year
|
|
Change From Baseline in Sleep Quality as Measured by the Pittsburgh Sleep Quality Index
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Total score on the Pittsburgh Sleep Quality Index questionnaire (range 0-21), where higher scores indicate poorer sleep quality
|
Baseline (pre-intervention), Perioperative, 1 year
|
|
Change From Baseline in Health-Related Quality of Life as Measured by the EORTC QLQ-C30 Questionnaire
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Global health status/Quality of life scale score (range 0-100) from the European Organisation for Research and Treatment of Cancer core questionnaire
|
Baseline (pre-intervention), Perioperative, 1 year
|
|
Change From Baseline in Fatigue Severity as Measured by the Functional Assessment of Chronic Illness Therapy - Fatigue Scale
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Total score on the 13-item fatigue subscale (range 0-52), where lower scores indicate higher levels of fatigue.
|
Baseline (pre-intervention), Perioperative, 1 year
|
|
Change From Baseline in Cardiorespiratory Fitness as Measured by Peak Oxygen Consumption (VO2 peak)
Time Frame: Baseline (pre-intervention), 1 year
|
Peak oxygen uptake measured in ml/kg/min during a cardiopulmonary exercise test on a cycle ergometer.
|
Baseline (pre-intervention), 1 year
|
|
Change From Baseline in Muscle Strength as Measured by Handgrip Dynamometry
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Maximum grip strength measured in kilograms (kg) using a calibrated handheld dynamometer.
|
Baseline (pre-intervention), Perioperative, 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Postoperative Respiratory Complications
Time Frame: Perioperative
|
Percentage of participants experiencing respiratory complications (e.g., pneumonia, respiratory failure) as defined by the Clavien-Dindo classification (Grade II or higher).
|
Perioperative
|
|
Incidence of Anastomotic Dehiscence
Time Frame: Perioperative
|
Percentage of participants with radiologically or clinically confirmed leakage at the site of surgical anastomosis.
|
Perioperative
|
|
Change From Baseline in Daily Physical Activity Level as Measured by Average Daily Step Count
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Average number of steps per day recorded by a digital pedometer/accelerometer.
|
Baseline (pre-intervention), Perioperative, 1 year
|
|
Change From Baseline in Lean Body Mass as Measured by Bioelectrical Impedance Analysis
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Total lean body mass measured in kilograms (kg) using a multi-frequency Bioelectrical Impedance Analysis device.
|
Baseline (pre-intervention), Perioperative, 1 year
|
|
Change From Baseline in Nutritional Intake (Protein Intake)
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Daily protein intake measured in grams per kilogram of body weight (g/kg/day) based on a 3-day food record.
|
Baseline (pre-intervention), Perioperative, 1 year
|
|
Change From Baseline in Psychological Distress as Measured by the Hospital Anxiety and Depression Scale
Time Frame: Baseline (pre-intervention), Perioperative, 1 year
|
Total score for anxiety and depression subscales (each range 0-21) to evaluate the impact of psychological support.
|
Baseline (pre-intervention), Perioperative, 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Radka Lordick Obermannová, Doc, MD, PhD, Masaryk Memorial Cancer Institute
Publications and helpful links
General Publications
- https://doi.org/10.1007/PL00007853
- Kawata S, Hiramatsu Y, Shirai Y, Watanabe K, Nagafusa T, Matsumoto T, Kikuchi H, Kamiya K, Takeuchi H. Multidisciplinary team management for prevention of pneumonia and long-term weight loss after esophagectomy: a single-center retrospective study. Esophagus. 2020 Jul;17(3):270-278. doi: 10.1007/s10388-020-00721-0. Epub 2020 Feb 6.
- 10.23736/S0393-3660.18.03986-4
- Adams SC, Schondorf R, Benoit J, Kilgour RD. Impact of cancer and chemotherapy on autonomic nervous system function and cardiovascular reactivity in young adults with cancer: a case-controlled feasibility study. BMC Cancer. 2015 May 18;15:414. doi: 10.1186/s12885-015-1418-3.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Stomach Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Stomach Neoplasms
- Esophageal Neoplasms
- Musculoskeletal Physiological Phenomena
- Musculoskeletal and Neural Physiological Phenomena
- Investigative Techniques
- Therapeutics
- Diagnostic Techniques and Procedures
- Diagnosis
- Surgical Procedures, Operative
- Public Health
- Environment and Public Health
- Population Characteristics
- Nutrition Therapy
- Health Status
- Demography
- Epidemiologic Measurements
- Perioperative Care
- Health
- Physical Fitness
- Quality of Life
- Enhanced Recovery After Surgery
- Clinical Laboratory Techniques
- Nutritional Support
- Cardiorespiratory Fitness
Other Study ID Numbers
- A12/23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
During the study, data will be managed in pseudonymized form in a protected database environment, available only for study team.
After completion of the study, the data will be fully anonymized for publication purposes. All publication outputs of the study will be carried out by a team of researchers led by the principal investigator. The submission of each publication is subject to the approval of the principal investigator.
The results of this study may be published or presented at scientific meetings after approval by the PI and always after anonymization of the subjects' personal data in accordance with Act No. 101/2000 Coll., on the protection of personal data.
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterCompletedGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterCompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Ukrainian Society of Clinical OncologyRecruitingGastric Cancer | Gastrectomy for Gastric Cancer | Gastric Cancer Stage III | Gastric Cancer Stage IIUkraine
-
Lin LiuRecruitingGastric Carcinoma | Gastric Neoplasm | Gastric Cancer Adenocarcinoma Metastatic | Gastric (cardia, Body) CancerChina
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
-
Shanghai Changzheng HospitalNot yet recruitingGastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastric Cancer
-
Ukrainian Society of Clinical OncologyRecruitingStomach Cancer | Gastric Cancer | Chemotherapy | Gastric Adenocarcinoma | Gastrectomy | Gastrointestinal Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Gastric Adenocarcinoma | GastroEsophageal Cancer | Stomach Neoplasm | Gastric Neoplasm | Advanced Gastric Carcinoma | Gastrectomy for Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma and other conditionsLithuania, Ukraine
Clinical Trials on Cardiorespiratory fitness (FsPS)
-
Sydney South West Area Health ServiceMotor Accidents Authority of NSWCompleted
-
Virginia Commonwealth UniversityAmerican Heart AssociationCompletedDiabetes Mellitus, Type 2 | Heart Failure, SystolicUnited States
-
University of GrazKarolinska Institutet; Medical University of GrazRecruiting
-
Hacettepe UniversityCompletedInflammation | Diabetes Mellitus, Type 2 | Prediabetic State | Cardiorespiratory Fitness | Exercise TestTurkey
-
Laboratory of Movement, Condorcet, Tournai, BelgiumCompleted
-
Michelle W. VossNational Institute on Aging (NIA)CompletedSedentary LifestyleUnited States
-
Sint MaartenskliniekRadboud University Medical CenterTerminatedExercise Training | Incomplete Spinal Cord InjuryNetherlands
-
Gaziler Physical Medicine and Rehabilitation Education...CompletedStroke, CardiovascularTurkey
-
I.M. Sechenov First Moscow State Medical UniversityCompletedQuality of Life | Metabolic Disturbance | Exercise Tolerance | Hypoxia, AltitudeRussian Federation
-
University of NottinghamCompletedCrohn DiseaseUnited Kingdom